 phase trial fluorouracil modul n-phosphonacetyl-l-aspart ribosid optim ribosid dose schedul biochem analysi sequenti tumor biopsi specimen preclin clinic studi select antitumor activ fluorouracil agent certain intracellular nucleotid pool combin n-phosphonacetyl-l-aspart pala pyrimidin nucleotid pool respons rate assess patient colorect carcinoma preclin tumor model ribosid mmpr inhibitor purin synthesi phosphoribosylpyrophosph prpp pool anabol nucleotid vivo addit mmpr therapeut efficaci phase trial optim dose schedul mmpr combin pala day infus day mmpr day patient solid tumor colorect breast toxic effect mild leukopenia mucos nausea rash patient mmpr diarrhea prpp orot acid releas assay tumor biopsi specimen hour hour mmpr dose patient addit mmpr prpp pool human solid tumor hour treatment patient twofold elev prpp mmpr dose level similar elev patient mmpr patient mmpr hour treatment result respect dose level mmpr patient patient patient administr dose level increas tumor prpp level toxic dose level dose level tumor level prpp hour hour patient time cours mmpr begin infus